Free Newsletter
Regulatory environment helps small biotech
Small biotechs may be suffering on the economic front, but there is some good news for these companies. While the FDA is still cautious, a third of the novel drugs approved between 2005 and 2007 came from small biotech companies, according to the RPM Report. And that's a trend that's likely to continue. "With the passage of the FDA Amendments Act last year, the FDA now has a tool (Risk Evaluation and Mitigation Strategies, or REMS) that allows it more ways to say 'yes' to new drugs--by placing extra restrictions that limit the patient population that can access the product," reports RPM. That means that while the FDA may not be approving these drugs for a broad, billion-dollar market--the kind that Big Pharmas love--biotechs developing drugs for a more select group of patients will do well. Pursuing a REMS approval is by no means easy, but there's an opportunity here for biotechs targeting a smaller specialty market that most Big Pharma companies would ignore
- see the article for more
Related Articles:
Crisis forces biotechs to cut R&D, preserve cash
FDA picking up the pace on '08 approvals
2008 NME approvals no better than last year?





